Differential actions of pituitary adenylyl cyclase-activating polypeptide and interferon gamma on Th2- and Th1-associated chemokine expression in cultured murine microglia.
Microglia are the immune cells that reside in the central nervous system (CNS). Following the facial nerve injury in the mouse, microglia are activated in the facial motor nucleus, coincident with an increase in the proinflammatory cytokine interferon-gamma (IFN-γ). The authors have previously shown that maximal facial motoneuron (FMN) survival after injury depends on the CD4(+)T-cell interaction with microglia. Furthermore, it appears that the anti-inflammatory T helper (Th) 2 CD4(+) T-cell subset is required in the facial nucleus, although the mechanism of CNS recruitment is not known. Pituitary adenylyl cyclase-activating polypeptide (PACAP) is a neuropeptide that has previously been demonstrated to be expressed by injured FMN. Interestingly, PACAP has been shown to act on peripheral macrophages by inducing chemokine expression capable of recruiting Th2 cells. Whether CNS-resident microglia, a related lineage to peripheral macrophages, respond to PACAP by expressing Th2-associated chemokines is not known. In this study, fluorescence-activated cell sorting was utilized to measure the frequency of microglia positive for different chemokines after exposure to various treatments. The results indicate that PACAP increases the frequency of microglia expressing Th2-associated chemokine, CCL11, and decreases the frequency of microglia expressing Th1-associated chemokine, CXCL11. In contrast, IFN-γ decreases the frequency of microglia expressing Th2-associated chemokine, CCL11, and increases the frequency of microglia expressing Th1-associated chemokine, CXCL11. Treatment with both PACAP and IFN-γ reversed the proinflammatory effect of IFN-γ. Given the recent focus on the therapeutic value of Th2 cells in the CNS during neurode-generative disease, PACAP may be a future therapeutic target for improving neuroregeneration after injury.
Wainwright
Derek A
DA
Department of Cell Biology, Neurobiology, and Anatomy, Loyola University Medical Center, Maywood, Illinois; Research and Development Service, Hines VA Hospital, Hines, Illinois.
Xin
Junping
J
Sanders
Virginia M
VM
Jones
Kathryn J
KJ
J Neurochem. 2007 Sep;102(6):2008-2019
17555556
J Leukoc Biol. 2003 Jan;73(1):155-64
12525573
J Immunol. 1999 Oct 1;163(7):3629-35
10490956
J Neuroinflammation. 2007 Feb 28;4:9
17328801
J Neuroimmunol. 2007 Mar;184(1-2):100-12
17198734
J Neurosci. 1998 Aug 1;18(15):5804-16
9671668
J Neurosci Res. 2003 Oct 15;74(2):240-7
14515353
Med Hypotheses. 2008;70(2):413-8
17582695
FASEB J. 2004 Sep;18(12):1453-5
15231725
J Immunol. 1989 Feb 1;142(3):760-5
2464024
J Immunol. 1999 Apr 15;162(8):4685-96
10202009
J Immunol. 2007 Jun 15;178(12):7525-9
17548586
J Neuroimmunol. 2002 Dec;133(1-2):81-94
12446011
Exp Neurol. 2006 Sep;201(1):212-24
16806176
Brain Behav Immun. 2003 Oct;17(5):393-402
12946661
J Neurosci Res. 1999 Sep 15;57(6):953-61
10467267
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10896-901
9724801
J Neuroimmunol. 1990 May;27(2-3):229-37
2110186
J Neuroimmunol. 2006 Mar;172(1-2):132-6
16376995
J Neurosci Res. 1999 Jan 1;55(1):127-34
9890441
J Leukoc Biol. 2004 Jun;75(6):1122-30
15020654
J Neurosci. 1999 Jun 1;19(11):RC7
10341268
Pharmacol Ther. 2003 May;98(2):245-55
12725872
J Neurosci. 2004 May 5;24(18):4333-9
15128847